SLC5A2 and Hypoglycemia: Patients at high risk of hypoglycemia may benefit from a combination of metformin-SGLT2 inhibitors, as the risk of hypoglycemia of the latter is low compared to treatment with insulin and sulfonylurea derivatives [30].